Medicare Enrolled

Dr. Nadya Hasham-Jiwa, D.O.

Medical Oncology · Houston, TX
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
11920 ASTORIA BLVD STE 240, Houston, TX 77089
8329321730
In practice since 2006 (19 years)
NPI: 1467401224 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Hasham-Jiwa from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Hasham-Jiwa? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Hasham-Jiwa

Dr. Nadya Hasham-Jiwa is a medical oncology specialist in Houston, TX, with 19 years of NPI registration. Based on federal Medicare data, Dr. Hasham-Jiwa performed 34,376 Medicare services across 382 unique beneficiaries.

Between the years covered by Open Payments, Dr. Hasham-Jiwa received a total of $8,622 from 58 pharmaceutical and/or device companies across 426 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in medical oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Hasham-Jiwa is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 19 years in practice ▲ Top 26% volume in TX $8,622 industry payments

Medicare Practice Summary

Medicare Utilization ↗
34,376
Medicare services
Top 26% in TX for medical oncology
382
Unique beneficiaries
$3
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~1,809 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Iron infusion (Feraheme) 19,380 $0 $2
Darbepoetin injection (Aranesp) for anemia 13,810 $2 $13
Office visit, established patient (30-39 min) 370 $91 $395
Drug injection, under skin or into muscle 152 $11 $53
Injection, zoledronic acid, 1 mg 150 $6 $37
Administration of chemotherapy into vein, 1 hour or less 133 $102 $416
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less 113 $23 $91
Office visit, established patient, complex (40-54 min) 106 $140 $555
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less 82 $50 $205
Office visit, established patient (20-29 min) 57 $64 $283
New patient office visit, complex (60-74 min) 23 $176 $687
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
56.9% high complexity
41.4% medium
1.6% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$8,622
Total received (2018-2024)
Avg $1,232/year across 7 years
Top 39% in TX for medical oncology
58
Companies
426
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,765 (90.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$857 (9.9%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$609
2023
$661
2022
$1,053
2021
$1,154
2020
$1,543
2019
$1,910
2018
$1,691

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$1,131
Merck Sharp & Dohme Corporation
$517
Amgen Inc.
$463
AstraZeneca Pharmaceuticals LP
$413
Celgene Corporation
$383
GENZYME CORPORATION
$377
PFIZER INC.
$355
Incyte Corporation
$355
Novartis Pharmaceuticals Corporation
$323
GlaxoSmithKline, LLC.
$278
Exelixis Inc.
$276
Rigel Pharmaceuticals, Inc.
$259
Seagen Inc.
$249
Pharmacyclics LLC, An AbbVie Company
$235
Janssen Biotech, Inc.
$230
Boehringer Ingelheim Pharmaceuticals, Inc.
$219
Genentech USA, Inc.
$206
Taiho Oncology, Inc.
$204
Lilly USA, LLC
$198
Gilead Sciences, Inc.
$195
Takeda Pharmaceuticals U.S.A., Inc.
$140
AMAG Pharmaceuticals, Inc.
$131
Puma Biotechnology, Inc.
$122
Astellas Pharma US Inc
$118
Deciphera Pharmaceuticals Inc.
$103
Apellis Pharmaceuticals, Inc.
$102
BeiGene USA, Inc.
$79
TAIHO ONCOLOGY, INC.
$78
Adaptive Biotechnologies Corporation
$65
SANOFI-AVENTIS U.S. LLC
$64
Bayer HealthCare Pharmaceuticals Inc.
$54
Alexion Pharmaceuticals, Inc.
$52
Teva Pharmaceuticals USA, Inc.
$49
MorphoSys, US Inc.
$45
TerSera Therapeutics LLC
$42
Tactile Systems Technology Inc
$36
Secura Bio, Inc.
$34
PUMA BIOTECHNOLOGY, INC.
$34
Regeneron Healthcare Solutions, Inc.
$33
Seattle Genetics, Inc.
$30
Pharmacosmos Therapeutics Inc.
$27
Pharmacyclics LLC, an AbbVie Company
$27
TESARO, Inc.
$24
AVEO Pharmaceuticals, Inc.
$22
Spectrum Pharmaceuticals Inc.
$22
Menarini Silicon Biosystems, Inc.
$21
PharmaEssentia USA Corporation
$21
Acceleron Pharma, Inc.
$20
Ipsen Biopharmaceuticals, Inc
$20
Octapharma USA, Inc.
$20
Sysmex Inostics Inc
$18
MEDIVATION FIELD SOLUTIONS LLC
$17
EISAI INC.
$15
Agios Pharmaceuticals, Inc.
$15
SpringWorks Therapeutics, Inc.
$15
Kite Pharma, Inc.
$15
Eisai Inc.
$15
Foundation Medicine, Inc.
$13
Top 3 companies account for 24.5% of total payments
Associated products mentioned in payments ›
ABECMA · ADCETRIS · AFINITOR · ALIMTA · Abraxane · Alecensa · Aliqopa · Aranesp · Avastin · BESREMI · BLENREP · BOSULIF · BRUKINSA · CABLIVI · CABOMETYX · CALQUENCE · COSELA · CYRAMZA · Cabometyx · Cellsearch · ELIQUIS · ELITEK · EMPLICITI · ENHERTU · ENJAYMO · ERBITUX · ERLEADA · Empaveli · Erleada · FARYDAK · FERAHEME · FLEXITOUCH · FOTIVDA · FOUNDATIONONE · Folotyn · GILOTRIF · GRANIX · Halaven · IBRANCE · IMBRUVICA · IMFINZI · INLYTA · INQOVI · INREBIC · Imbruvica · JADENU · JAKAFI · JEVTANA · KANJINTI · KEYTRUDA · KISQALI · Kadcyla · Kyprolis · LIBTAYO · LONSURF · LUMAKRAS · LYNPARZA · Lenvima · Lonsurf · Lunsumio · MEKINIST · MONJUVI · MONOFERRIC · NERLYNX · NINLARO · Nerlynx · Nplate · OCTAGAM · OGSIVEO · OJJAARA · OPDIVO · OPDUALAG · PADCEV · PIQRAY · PROMACTA · Polivy · Pomalyst · QINLOCK · REBLOZYL · Reblozyl · Revlimid · Rezlidhia · SARCLISA · SOMATULINE DEPOT · Stivarga · TAGRISSO · TECENTRIQ · TIBSOVO · TUKYSA · TUMOR LYSIS SYNDROME - DISEASE · Tavalisse · Tecentriq · Trodelvy · Truxima · ULTOMIRIS · VERZENIO · VOTRIENT · Vectibix · Venclexta · XALKORI · XTANDI · Xofigo · Xospata · ZEJULA · ZOLADEX · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (90%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $25 per 100 Medicare services performed
Looking for a medical oncology specialist in Houston?
Compare medical oncologists in the Houston area by procedure volume, costs, and industry payment transparency.
Browse medical oncologists nearby

Geographic Context

Medical oncologists within 10 mi
179
Per 100K population
3.8
County median income
$73,104
Nearest hospital
HCA HOUSTON HEALTHCARE SOUTHEAST
4.7 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Hasham-Jiwa is a mixed practice specialist, with above-average Medicare volume (top 26% in TX), with low-engagement industry engagement, with 19 years of NPI registration.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Hasham-Jiwa experienced with iron infusion (feraheme)?
Based on Medicare claims data, Dr. Hasham-Jiwa performed 19,380 iron infusion (feraheme) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Hasham-Jiwa receive payments from pharmaceutical companies?
Yes. Dr. Hasham-Jiwa received a total of $8,622 from 58 companies across 426 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Hasham-Jiwa's costs compare to other medical oncologists in Houston?
Dr. Hasham-Jiwa's average Medicare payment per service is $3. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Hasham-Jiwa) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →